Related Experiment Video
Updated: Oct 8, 2025

Author Spotlight: Unveiling Cellular Functions and Potential Clinical Implications of Leptomeningeal Lymphatic Endothelial Cells
Published on: September 8, 2023
Primary Leptomeningeal B-cell Lymphoma in an Immunocompetent Adult: Case Report
Andrea Calderon-Castro1, Leonardo Enciso2,3, Rafael Tejada-Cabrera4
1Neurology, Hospital Universitario Nacional de Colombia, Bogotá, COL.
Abstract:
Primary leptomeningeal lymphoma (PLML) is a rare disease, comprising less than 1% of all lymphomas. Clinical manifestations include headache, encephalopathy, ataxia, cranial nerve palsy, and myelitis. Diagnosis requires a combination of magnetic resonance images (MRI), cytology, flow cytometry of cerebrospinal fluid (CSF), and an extensive workup to rule out systemic lymphoma. We describe the case of a 49-year-old man who developed subacute onset headache, encephalopathy, and blindness. Whole-body examinations, including a bone marrow trephine biopsy, excluded systemic lymphoma. Brain MRI showed leptomeningeal enhancement. Cytology and flow cytometry of CSF found a clonal B-cell population making a diagnosis of PLML. He began treatment with rituximab and high-dose methotrexate (HD-MTX), with progressive clinical improvement. CSF analysis after two cycles and one intrathecal methotrexate dose was normal. Brain and spinal MRI images plus CSF analysis, along with an extensive workup to exclude systemic lymphoma, are necessary to diagnose PLM. Early treatment with HD-MTX alone or in combination with rituximab improves clinical outcomes.
Insights
Primary leptomeningeal lymphoma (PLML) is a rare cancer affecting the brain and spinal cord lining. Early diagnosis and treatment with high-dose methotrexate and rituximab can significantly improve patient outcomes.
Area of Science:
- Neurology
- Oncology
- Hematology
Background:
- Primary leptomeningeal lymphoma (PLML) is a rare neoplastic condition, accounting for less than 1% of all lymphomas.
- Clinical symptoms include headache, encephalopathy, ataxia, cranial nerve palsy, and myelitis, often necessitating extensive diagnostic workup.
Observation:
- A 49-year-old male presented with subacute headache, encephalopathy, and blindness.
- Systemic lymphoma was excluded via whole-body examinations and bone marrow biopsy.
- Brain MRI revealed leptomeningeal enhancement, and CSF analysis identified a clonal B-cell population, confirming PLML.
Findings:
- Treatment initiated with rituximab and high-dose methotrexate (HD-MTX) resulted in progressive clinical improvement.
- Post-treatment CSF analysis and imaging demonstrated normalization of findings after two cycles of therapy and one intrathecal methotrexate dose.
Implications:
- Accurate diagnosis of PLML requires integrating MRI, CSF cytology, flow cytometry, and exclusion of systemic disease.
- Early therapeutic intervention utilizing HD-MTX, with or without rituximab, is associated with improved clinical outcomes in PLML patients.
Related Concept Videos
Primary Lymphoid Organs
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
Cells of the Adaptive Immune Response

